Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.

Inclusion Criteria:

* § Age \> or equal to 18 years.§
* Performance status inferior or equal to 1 (WHO criteria)
* Histologically proven breast cancer, non metastatic, with clinical tumor diameter \> or equal to 2 cm.
* HR negative and HER 2 negative.
* Clinical stage II and IIIa.
* Non prior treated patients either by surgery, radiotherapy, hormonotherapy or chemotherapy.§
* Adequate hematological, renal and hepatic functions : neutrophils \> 2.109 /L, platelets \> 100.109 /L, Hb \> 10 g/dL, normal bilirubin, ASAT and ALAT inferior or equal to 2,5 ULN (upper normal limit), alkaline phosphatases £ 2,5 ULN, creatinine \< 140 µmol/L or creatinine clearance \> 60 mL/min.§
* Written informed consent§
* Affiliation with social security system (or profit being of such a mode) according to terms' of the law of August 9, 2004.

Exclusion Criteria:

* Male patient.
* Pregnant or lactating women or childbearing potential with no efficacy contraception.
* Other breast cancer form and particularly inflammatory form and/or negliged (T4b or T4d).§
* Non measurable tumor.
* Prior surgery or primary axillary dissection.
* Prior treatment for this new breast cancer.
* Under guardianship patient
* Patient with antecedent of second cancer, excepted in situ uterine carcinoma or baso-cellular cutaneous cancer considered as definitively cured.
* Patient with an associated pathology considered incompatible with the study.§ Cardiac, renal, medullar, respiratory or hepatic insufficiency.
* Significant neurological or psychiatric troubles.§ Symptomatic or evolutive troubles in CNS or metastasis.
* Peripheral neuropathy \> grade 2 NCI-CTC (version 3.0)
* Previous allergy with polysorbate 80.
* Concomitant treatment with a drug tested in a clinical trial, participation to another clinical study, for the last thirty days or prior chemotherapy.
* Patients non stable for the following 6 months or leaving at a great distance of the participating center.